Alternative performance measures
This report contains financial key figures in accordance with the frameworks applied by AddLife, which are based on IFRS. In addition, there are alternative performance measures (APM) that cannot be directly extracted or derived from the financial statements. These key figures are essential for understanding and evaluating AddLife's operations and financial position. They should not be seen as a replacement for the measures defined according to IFRS but rather as a complement to the financial reporting. Since not all companies calculate financial measures in the same way, these are not always comparable with measures used by other companies. The key figures are presented below and commented on in other parts of the interim report.
Return on equity
| Jun 30 | Jun 30 | Dec 31 | |
| SEKm | 2025 | 2024 | 2024 |
| Profit/loss for the period (roll 12 months) | 339 | 120 | 254 |
| Average equity | 5,198 | 5,154 | 5,147 |
| Return on equity, % | 7 | 2 | 5 |
Return on working capital (P/WC)
| Jun 30 | Jun 30 | Dec 31 | |
| SEKm | 2025 | 2024 | 2024 |
| EBITA (roll 12 months) | 1,219 | 1,112 | 1,159 |
| Inventories, average | 1,748 | 1,778 | 1,743 |
| Accounts receivable, average | 1,556 | 1,506 | 1,537 |
| Accounts payable, average | -1,024 | -952 | -996 |
| Working capital, average | 2,280 | 2,332 | 2,284 |
| Return on working capital, % | 53 | 48 | 51 |
EBITA and EBITDA
| Q2 | Q2 | Jan-Jun | Jan-Jun | Jul 2024- | Full year | |
| SEKm | 2025 | 2024 | 2025 | 2024 | Jun 2025 | 2024 |
| Operating profit | 200 | 192 | 435 | 378 | 778 | 721 |
| Amortization and impairment of intangible assets | 107 | 107 | 215 | 212 | 441 | 438 |
| EBITA | 307 | 299 | 650 | 590 | 1,219 | 1,159 |
| Depreciation and impairment of tangible assets | 94 | 91 | 186 | 184 | 376 | 374 |
| EBITDA | 401 | 390 | 836 | 774 | 1,595 | 1,533 |
Adjusted EBITA
| Q2 | Q2 | Jan-Jun | Jan-Jun | Jul 2024- | Full year | |
| SEKm | 2025 | 2024 | 2025 | 2024 | Jun 2025 | 2024 |
| EBITA | 307 | 299 | 650 | 590 | 1,219 | 1,159 |
| One-off costs | ||||||
| Restructuring reserve Camanio | – | – | – | 6 | 4 | 10 |
| Revalued contingent consideration | – | -7 | – | -7 | 3 | -4 |
| Adjusted EBITA | 307 | 292 | 650 | 589 | 1,226 | 1,165 |
EBITA margin / Adjusted EBITA margin
| Q2 | Q2 | Jan-Jun | Jan-Jun | Jul 2024- | Full year | |
| SEKm | 2025 | 2024 | 2025 | 2024 | Jun 2025 | 2024 |
| EBITA | 307 | 299 | 650 | 590 | 1,219 | 1,159 |
| Net sales | 2,578 | 2,554 | 5,280 | 5,124 | 10,442 | 10,286 |
| EBITA margin, % | 11.9 | 11.7 | 12.3 | 11.5 | 11.7 | 11.3 |
| Adjusted EBITA | 307 | 292 | 650 | 589 | 1,226 | 1,165 |
| Adjusted EBITA margin, % | 11.9 | 11.4 | 12.3 | 11.5 | 11.7 | 11.3 |
Organic growth
| Labtech | Medtech | The Group¹ | ||||||
| Q2 | Q2 | Q2 | Q2 | Q2 | Q2 | |||
| % | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||
| Total growth | 4.8 | 7.8 | -1.4 | 8.0 | 0.9 | 8.0 | ||
| (-) Currency effect | -4.0 | 0.1 | -4.5 | 0.8 | -4.2 | 0.5 | ||
| (-) Acquired growth | 2.7 | – | 1.5 | – | 1.9 | – | ||
| Organic growth | 6.1 | 7.7 | 1.6 | 7.2 | 3.2 | 7.5 | ||
| Labtech | Medtech | The Group¹ | ||||||
| Q2 | Q2 | Q2 | Q2 | Q2 | Q2 | |||
| SEKm | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||
| Total growth | 44 | 69 | -21 | 119 | 24 | 189 | ||
| (-) Currency effect | -38 | 1 | -70 | 11 | -110 | 12 | ||
| (-) Acquired growth | 25 | – | 24 | – | 50 | – | ||
| Organic growth | 57 | 68 | 25 | 108 | 84 | 177 | ||
| Labtech | Medtech | The Group¹ | ||||||
| Jan-Jun | Jan-Jun | Jan-Jun | Jan-Jun | Jan-Jun | Jan-Jun | |||
| % | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||
| Total growth | 9.4 | 1.5 | -0.5 | 9.0 | 3.0 | 6.3 | ||
| (-) Currency effect | -2.4 | 0.1 | -2.2 | 1.2 | -2.3 | 0.8 | ||
| (-) Acquired growth | 2.8 | – | 0.7 | – | 1.5 | – | ||
| Organic growth | 9.0 | 1.4 | 1.0 | 7.8 | 3.8 | 5.5 | ||
| Labtech | Medtech | The Group¹ | ||||||
| Jan-Jun | Jan-Jun | Jan-Jun | Jan-Jun | Jan-Jun | Jan-Jun | |||
| SEKm | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||
| Total growth | 170 | 27 | -15 | 273 | 156 | 302 | ||
| (-) Currency effect | -44 | 3 | -72 | 34 | -116 | 37 | ||
| (-) Acquired growth | 52 | – | 24 | – | 76 | – | ||
| Organic growth | 162 | 24 | 33 | 239 | 196 | 265 | ||
| ¹The Group includes eliminations | ||||||||
Profit growth EBITA
| Jun 30 | Jun 30 | Dec 31 | |
| SEKm | 2025 | 2024 | 2024 |
| EBITA (roll 12 months) | 1,219 | 1,112 | 1,159 |
| (-) Previous year's EBITA (rolling 12 months) | 1,112 | 1,158 | 1,135 |
| EBITA growth | 107 | -46 | 24 |
| Profit growth EBITA, % | 10 | -4 | 2 |
Financial net liabilities and Net debt/equity ratio
| Jun 30 | Jun 30 | Dec 31 | |
| SEKm | 2025 | 2024 | 2024 |
| Borrowing | 4,410 | 4,793 | 4,434 |
| Cash and cash equivalents | -253 | -242 | -331 |
| Financial net debt | 4,157 | 4,551 | 4,103 |
| Pension liability | 62 | 63 | 62 |
| Lease liability | 518 | 546 | 531 |
| Contingent considerations | 107 | 41 | 106 |
| Provisions | 29 | 116 | 118 |
| Net interest-bearing deb | 4,873 | 5,317 | 4,920 |
| Total equity | 5,268 | 5,141 | 5,309 |
| Net debt/equity ratio, multiple | 0.9 | 1.0 | 0.9 |
Financial net liabilities/EBlTDA
| Jun 30 | Jun 30 | Dec 31 | |
| SEKm | 2025 | 2024 | 2024 |
| Net interest-bearing deb | 4,873 | 5,317 | 4,920 |
| EBITDA (roll 12 months) | 1,595 | 1,488 | 1,533 |
| Financial net liabilities/EBITDA, multiple | 3.1 | 3.6 | 3.2 |
Equity ratio
| Jun 30 | Jun 30 | Dec 31 | |
| SEKm | 2025 | 2024 | 2024 |
| Total equity | 5,268 | 5,141 | 5,309 |
| Total assets | 12,751 | 13,027 | 13,055 |
| Equity ratio, % | 41 | 39 | 41 |
Latest updated: 7/14/2025 3:39:18 PM by Johanna Prim